Journal List > J Korean Ophthalmol Soc > v.53(3) > 1009312

TOOLS
Kim, Kim, Lew, Kim, Cho, and Lee: Effect of Intravitreal Injection as a Primary Treatment in Cystoid Macular Edema after Cataract Surgery
Original Article
Journal of the Korean Ophthalmological Society

Journal of the Korean Ophthalmological Society 2012; 53(3): 428-433.

Published online: 15 March 2012

DOI: https://doi.org/10.3341/jkos.2012.53.3.428

Effect of Intravitreal Injection as a Primary Treatment in Cystoid Macular Edema after Cataract Surgery

Joo Yeon Kim, MD1, Joung Mok Kim, MD2, Young Ju Lew, MD, PhD1, Chul Gu Kim, MD1, Sung Won Cho, MD, PhD1, Tae Gon Lee, MD3

1Myung-Gok Eye Research Institute, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea.

2Seoul Bright Eye Clinic, Seoul, Korea.

3Department of Ophthalmology, Konyang University Hospital, Daejeon, Korea.

Address reprint requests to Young Ju Lew, MD, PhD. Kim's Eye Hospital, #136 Yeongsin-ro, Yeongdeungpo-gu, Seoul 150-902, Korea. Tel: 82-2-2639-7777, Fax: 82-2-2633-3976, yjlew@kimeye.com

Received 23 February 2011       Accepted 22 February 2012

Copyright © 2012 The Korean Ophthalmological Society

Abstract

Purpose

To report the clinical manifestations of intravitreal triamcinolone injection as a primary treatment method for patients with cystoid macular edema after cataract surgery.

Methods

The present retrospective study was comprised of patients diagnosed with cystoid macular edema after cataract surgery performed between March 2006 and March 2008. To treat the edema, intravitreal triamcinolone injection was administered. Best corrected visual acuity (BCVA) and central macular thickness were measured, and complications as well as efficacy of the treatment were evaluated.

Results

Twelve eyes were selected for the present study with a mean patient age of 67.3 years. The average period between cataract surgery and diagnosis of cystoid macular edema was 7.6 weeks. All 12 eyes received an intravitreal triamcinolone injection, and the patients were followed up for an average of 6.7 months. BCVA (log MAR) was changed from 0.29 ± 0.12 to 0.11 ± 0.09, showing statistically significant improvement (p = 0.000). The OCT showed that the average CMT was statistically decreased from 390.58 ± 94.98 µm to 165.17 ± 39.95 µm (p = 0.001). No complications were reported after the procedure, and vision and edema improved after one month in all 12 eyes.

Conclusions

After performing intravitreal triamcinolone injection as a primary treatment method for cystoid macular edema which developed after cataract surgery, rapid recovery and improvement of vision and macular thickness were confirmed in all 12 eyes.

Keywords: Cystoid macular edema, Pseudophakia, Triamcinolone

Figures and Tables

Figure 1
A 61-year-old male patient who presented with visual disturbance in his left eye that had undergone cataract surgery 12 weeks previously. BCVA was 0.2 log MAR and CME was seen on the OCT (A, CMT 399 µm) and FAG (B). After intravitreal triamcinolone acetonide injection, BCVA was improved to 0.1 log MAR and CME was resolved (C, CMT 132 µm), 2 months after the injection. BCVA = best corrected visual acuity; CME = cystroid macular edema; OCT = optical coherence tomography; CMT = central macular thickness; FAG = fluorescein angiography.
jkos-53-428-g001
Figure 2
A 63-year-old male patient who presented with visual disturbance in his right eye that had undergone cataract surgery 8 weeks earlier. BCVA was 0.7 log MAR and CME was seen on the on the OCT (A, CMT 415 µm) and FAG (B). After 1 month after intravitreal triamcinolone injection, CME was still maintained (C, CMT 514 µm). Secondary intravitreal triamcinolone and bevacizumab injection was done and CME resolved 1 month after the secondary injection (D, CMT 182 µm). BCVA = best corrected visual acuity; CME = cystroid macular edema; OCT = optical coherence tomography; CMT = central macular thickness; FAG = fluorescein angiography.
jkos-53-428-g002
Table 1
Basic demographics for patients
jkos-53-428-i001

Values are presented as mean ± SD or number.

OD = right eye; OS = left eye; DM = diabetic mellitus; HTN = hypertension.

Table 2
Changes in visual acuity and central macular thickness before and after the intravitreal triamcinolone injection in 12 patients with pseudophakic cystoid macular edema
jkos-53-428-i002

VA = visual acuity; CMT = central macular thickness.

Table 3
The effect of invitravitreal triancinolone injection in patients with pseudophakic cystoid macular edema: comparison of mean BCVA and CMT (n = 12)
jkos-53-428-i003

Values are presented as mean ± SD.

BCVA = best corrected visual acuity; CMT = central macular thickness.

*Paired t-test.

References

1. Gass JD, Norton EW. Cystoid macular edema and papilledema following cataract extraction. A fluorescein funduscopic and angiographic study. 1966. Arch Ophthalmol. 1966. 76:646–661.
2. Jaffe NS. Cataract Surgery and Its Complications. 1984. 4th ed. St. Louis: Mosby;426–441.
3. Kim JC, Lim DG. Cystoid macular edema in pseudophakia. J Korean Ophthalmol Soc. 1990. 31:1148–1151.
4. Drolsum L, Haaskjold E. Causes of decreased visual acuity after cataract extraction. J Cataract Refract Surg. 1995. 21:59–63.
5. Flach AJ. The incidence, pathogenesis, and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998. 96:557–634.
6. Levin DS, Lim JI. Update on pseudophakic cystoid macular edema treatment options. Ophthalmol Clin North Am. 2002. 15:467–472.
7. Stark WJ Jr, Maumenee AE, Fagadau W, et al. Cystoid macular edema in pseudophakia. Surv Ophthalmol. 1984. 28:Suppl. 442–451.
8. Arevalo JF, Maia M, Garcia-Amaris RA, et al. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group Results. Ophthalmology. 2009. 116:1481–1487.
9. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998. 96:557–634.
10. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002. 47:Suppl 1. S203–S218.
11. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol. 1987. 103:479–486.
12. Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol. 1991. 112:514–519.
13. Shulman S, Ferencz JR, Gilady G, et al. Prognostic factors for visual acuity improvement after intravitreal triamcinolone injection. Eye (Lond). 2007. 21:1067–1070.
14. Koutsandrea C, Moschos MM, Brouzas D, et al. Intraocular triancinolone acetonide for pseudophakic cystoids macular edema: optical coherence tomography and multifocal electroretinography study. Retina. 2007. 27:159–164.
15. Karacorlu M, Ozdemir H, Karacorlu S. Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand. 2003. 81:648–652.
16. Negi AK, Vernon SA, Lim CS, Owen-Armstrong K. Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation. Eye (Lond). 2005. 19:747–751.
17. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2006. 244:309–315.
18. Mason JO 3rd, Albert MA Jr, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina. 2006. 26:356–357.
19. Barone A, Prascina F, Russo V, et al. Successful treatment of pseudophakic cystoid macular edema with intravitreal bevacizumab. J Cataract Refract Surg. 2008. 34:1210–1212.
TOOLS
Similar articles